ArriVent Biopharma (AVBP)

Executive Summary

ArriVent Biopharma is a clinical-stage oncology company focused on developing innovative therapeutics for underserved cancers, particularly non-small cell lung cancer (NSCLC). Its lead asset, furmonertinib, is a next-generation EGFR tyrosine kinase inhibitor designed to overcome resistance mutations, including EGFR exon20 insertions (exon20ins), which lack approved targeted therapies. The pivotal Phase 3 FURVENT trial (NCT05607550) is evaluating furmonertinib plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for EGFR exon20ins NSCLC, with enrollment completed and top-line results anticipated in the second half of 2026. Additionally, ArriVent is advancing MRG007, an antibody-drug conjugate targeting solid tumors, in a Phase 1 trial (NCT07066657) with initial data expected in 2026. The company also has an adjuvant Phase 3 study of furmonertinib in resected EGFR-mutant NSCLC. With a capital-efficient model and global in-licensing strategy, ArriVent is positioned to address key resistance mechanisms and expand its pipeline. Upcoming catalysts include the FURVENT data readout and early MRG007 results, which could drive significant value.

Upcoming Catalysts (preview)

• H2 2026Phase 3 FURVENT Top-line Data in EGFR Exon20ins NSCLC60% success
• 2026Initial Phase 1 Data for MRG007 ADC in Solid Tumors40% success
• H2 2027Potential Accelerated Approval Filing for Furmonertinib in EGFR Exon20ins NSCLC50% success